References
- Gunnarsson C, Chen J, Rizzo JA, et al. The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey. J Dermatolog Treat 2012;23:240-54
- Raval K, Lofland JH, Waters H, et al. Disease and treatment burden of psoriasis: examining the impact of biologics. J Drugs Dermatol 2011;10:189-96
- Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004;9:136-9
- Disorders, National Institute of Arthritis and Muscoloskeletal and Skin. Questions and answers about psoriasis. 2015. https://www.niams.nih.gov/health_info/psoriasis/. Accessed July 26, 2015
- Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica 1974;148:1-18
- Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 2008;59:772-80
- Lewis-Beck C, Abouzaid S, Xie L, et al. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Prefer Adherence 2013;7:199-205
- Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005;64(Suppl2):ii18-23
- Foundation, National Psoriasis. About psoriasis. 2015. https://www.psoriasis.org/about-psoriasis. Accessed July 26, 2015
- Crown WH. The cost of psoriasis. Manag Care 2013;12:10-13; discussion 20–1
- Kimball AB, Yu AP, Signorovitch J, et al. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol 2012;66:e67-76
- Zachariae H, Zachariae R, Blomqvist K, et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 2002;82:108-13
- Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50
- Yu AP, Tang J, Xie J, et al. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin 2009;25:2429-38
- Foundation, National Psoriasis. Topical treatments. 2015. https://www.psoriasis.org/about-psoriasis/treatments/topicals. July 26, 2015
- Foundation, National Psoriasis. Moderate to severe psoriasis and psoriatic arthritis: Biologic drugs. 2015. https://www.psoriasis.org/about-psoriasis/treatments/biologics. Accessed July 26, 2015
- Foundation, National Psoriasis. Traditional systemic medications. 2015. https://www.psoriasis.org/about-psoriasis/treatments/systemics. Accessed July 26, 2015
- Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-85
- Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol 2015;151:651-8
- Feldman SR, Zhao Y, Shi L, et al. Economic and comorbidity burden among patients with moderate-to-severe psoriasis. J Manag Care Spec Pharm 2015;21:874-88
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
- Lin H, Lucas PT, Feldman SR, et al. Medication use and associated health care outcomes and costs for patients with psoriasis in the United States. J Dermatol Treat 2012;23:196-202
- Kimball AB, Guérin A, Tsaneva M, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol 2011;25:157-63
- Wu, JJ, Guérin A, Gauthier G, et al. Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study. J Dermatol Treat 2016;15:1-9